Literature DB >> 17201159

Decreased expression of tumor protein p53-induced nuclear protein 1 (TP53INP1) in breast carcinoma.

Yasuhiro Ito1, Yoshiharu Motoo, Hiroshi Yoshida, Juan Lucio Iovanna, Yuuki Takamura, Akihiro Miya, Kanji Kuma, Akira Miyauchi.   

Abstract

BACKGROUND: Tumor protein p53-induced nuclear protein 1 (TP53INP1) is a stress-induced protein and plays a role in cell cycle arrest and p53-mediated apoptosis. In this study, TP53INP1 expression in human breast carcinoma was investigated.
MATERIALS AND METHODS: TP53INP1 and aberrant p53 expression were investigated immunohistochemically in 81 cases of breast carcinoma.
RESULTS: Diffuse and intense TP53INP1 expression was observed in the normal mammary gland. Decreased TP53INP1 expression was found in 45 cases (55.6%) of breast carcinoma. The TP53INP1 expression level was inversely linked to tumor size, positive lymph node metastasis, high histological grade and aberrant p53 expression.
CONCLUSION: Decreased expression of TP53INP1 is involved in breast carcinoma progression.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17201159

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  16 in total

1.  miR-190-mediated downregulation of PHLPP contributes to arsenic-induced Akt activation and carcinogenesis.

Authors:  Kevin Beezhold; Jia Liu; Hong Kan; Terry Meighan; Vince Castranova; Xianglin Shi; Fei Chen
Journal:  Toxicol Sci       Date:  2011-07-12       Impact factor: 4.849

2.  Development of an ELISA detecting Tumor Protein 53-Induced Nuclear Protein 1 in serum of prostate cancer patients.

Authors:  Houda Saadi; Marion Seillier; Maria José Sandi; Sylvain Peuget; Christine Kellenberger; Gwenaëlle Gravis; Nelson J Dusetti; Juan L Iovanna; Palma Rocchi; Mohamed Amri; Alice Carrier
Journal:  Results Immunol       Date:  2013-05-28

3.  Tumor protein p53-induced nuclear protein (TP53INP1) expression in medullary thyroid carcinoma: a molecular guide to the optimal extent of surgery?

Authors:  D Taïeb; S Giusiano; F Sebag; M Marcy; C de Micco; F F Palazzo; N J Dusetti; J L Iovanna; J F Henry; S Garcia; Colette Taranger-Charpin
Journal:  World J Surg       Date:  2010-04       Impact factor: 3.352

4.  microRNA-155 acts as an oncogene by targeting the tumor protein 53-induced nuclear protein 1 in esophageal squamous cell carcinoma.

Authors:  Jie Zhang; Chen Cheng; Xiang Yuan; Jiang-Tu He; Qiu-Hui Pan; Fen-Yong Sun
Journal:  Int J Clin Exp Pathol       Date:  2014-01-15

5.  Roles for microRNAs, miR-93 and miR-130b, and tumor protein 53-induced nuclear protein 1 tumor suppressor in cell growth dysregulation by human T-cell lymphotrophic virus 1.

Authors:  Man Lung Yeung; Jun-ichirou Yasunaga; Yamina Bennasser; Nelson Dusetti; David Harris; Nafees Ahmad; Masao Matsuoka; Kuan-Teh Jeang
Journal:  Cancer Res       Date:  2008-11-01       Impact factor: 12.701

6.  17β-estradiol up-regulates miR-155 expression and reduces TP53INP1 expression in MCF-7 breast cancer cells.

Authors:  Chunmei Zhang; Jing Zhao; Huayu Deng
Journal:  Mol Cell Biochem       Date:  2013-04-09       Impact factor: 3.396

7.  MiR-125b promotes proliferation and migration of type II endometrial carcinoma cells through targeting TP53INP1 tumor suppressor in vitro and in vivo.

Authors:  Feizhou Jiang; Te Liu; Yinyan He; Qin Yan; Xiaoyue Chen; Hui Wang; Xiaoping Wan
Journal:  BMC Cancer       Date:  2011-10-05       Impact factor: 4.430

8.  MiR-34a expression has an effect for lower risk of metastasis and associates with expression patterns predicting clinical outcome in breast cancer.

Authors:  Hanna Peurala; Dario Greco; Tuomas Heikkinen; Sippy Kaur; Jirina Bartkova; Maral Jamshidi; Kristiina Aittomäki; Päivi Heikkilä; Jiri Bartek; Carl Blomqvist; Ralf Bützow; Heli Nevanlinna
Journal:  PLoS One       Date:  2011-11-10       Impact factor: 3.240

9.  An integrative genomic analysis revealed the relevance of microRNA and gene expression for drug-resistance in human breast cancer cells.

Authors:  Yusuke Yamamoto; Yusuke Yoshioka; Kaho Minoura; Ryou-u Takahashi; Fumitaka Takeshita; Toshiki Taya; Reiko Horii; Yayoi Fukuoka; Takashi Kato; Nobuyoshi Kosaka; Takahiro Ochiya
Journal:  Mol Cancer       Date:  2011-11-03       Impact factor: 27.401

Review 10.  How HTLV-1 may subvert miRNAs for persistence and transformation.

Authors:  Amel B Bouzar; Luc Willems
Journal:  Retrovirology       Date:  2008-11-12       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.